多囊卵巢综合征女性的性功能障碍:病例对照研究
该前瞻性观察性病例对照研究纳入135名女性(68例多囊卵巢综合征(PCOS),67例对照),于2017年3月至2020年3月开展。PCOS女性报告更严重的性功能障碍和性困扰,但雄激素水平与性功能仅见少量弱关联。
要点
- PCOS女性性功能障碍比例41.2%,对照组11.9%(P<0.001)。
- PCOS女性临床性困扰比例51.5%,对照组19.4%(P<0.001)。
- 雄激素水平与性功能关联弱,回归模型最多解释15%的性功能变异。
核心结论
- PCOS女性性功能受损,但内分泌紊乱对性功能的直接影响似乎很小。
- 作者认为在PCOS女性的临床照护中,关注性欲问题并提供心理性咨询很重要。
研究设计与样本
- 前瞻性观察性病例对照研究,纳入135名女性(68例PCOS,67例对照),于2017年3月至2020年3月开展。
- 研究对象为18-40岁、有稳定异性恋关系且无合并症的PCOS女性和非PCOS女性,接受液相色谱-串联质谱的内分泌筛查和经过验证的性功能问卷。
主要发现
- PCOS女性性功能显著更低(女性性功能指数(FSFI)P<0.001,偏η²=0.104),性困扰水平更高(女性性困扰量表修订版 P<0.001,偏η²=0.090)。
- PCOS女性更常符合性功能障碍定义(41.2% vs 11.9%,P<0.001,Phi V=0.331)和临床性困扰(51.5% vs 19.4%,P<0.001,Phi V=0.335)。
- 校正混杂因素后的回归分析显示雄激素水平与性功能仅见少量弱关联,每个模型最多解释15%的性功能。
- 存在显著的分组×激素交互作用后,PCOS组内分析未见显著关联。
- 对照组中,睾酮与FSFI疼痛维度呈弱负关联(β=-6.022,P=0.044,Adj R²=0.050),游离雄激素指数与FSFI性高潮维度呈弱负关联(β=-3.360,P=0.023,Adj R²=0.049),雄烯二酮与临床性困扰呈弱负关联(β=-7.293,P=0.036,exp(β)=0.001)。
临床怎么用
- 作者认为,在PCOS女性的临床照护中,关注性欲问题并提供心理性咨询很重要。
局限性
- 研究聚焦于性功能可能产生选择偏倚。
- 性功能障碍更严重的女性可能选择参与或不参与。
- PCOS女性与对照组在关系持续时间和激素避孕药使用上的差异可能使性功能结果产生偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What is the relationship of sex steroid levels with sexual function in women with and without polycystic ovary syndrome (PCOS)? SUMMARY ANSWER: Women with PCOS reported more sexual dysfunction and more sexual distress compared to those without PCOS, but only few and weak associations between androgen levels and sexual function were observed. WHAT IS KNOWN ALREADY: The literature shows that women with PCOS report lower levels of sexual function and sexual satisfactionand more sexual distress. Contributing factors seem to be obesity, alopecia, hirsutism, acne, infertility, anxiety, depression, and low self-esteem. In women with PCOS clinical and/or biochemical hyperandrogenism is common; its relationship with sexualfunction is, however, inconclusive. STUDY DESIGN, SIZE, DURATION: This observational prospective case control study with 135 women (68 PCOS, 67 control) was conductedfrom March 2017 until March 2020. PARTICIPANTS/MATERIALS, SETTING, METHODS: Heterosexual women with and without PCOS, aged 18-40 years, in a steady relationshipand without any comorbidities, underwent an extensive medical and endocrine screening using liquid chromatography-tandem mass spectrometry and validated sexual function questionnaires. MAIN RESULTS AND THE ROLE OF CHANCE: Women with PCOS reported significantly lower sexual function (Female Sexual Function Index (FSFI) P < 0.001, partial η2 = 0.104), higher levels of sexual distress (Female Sexual Distress Scale-Revised P < 0.001, partial η2 = 0.090), and they more often complied with the definition of sexual dysfunction (41.2% vs 11.9%, P < 0.001, Phi V = 0.331) and clinical sexual distress (51.5% vs 19.4%, P < 0.001, Phi V = 0.335). Regression analysis adjusted for confounders showed only few and weak associations between androgen levels and sexual function, with each model explaining a maximum of 15% sexual function. Following significant Group × Hormone interactions, analyses for both groups separately showed no significant associations in the PCOS group. The control group showed only weak negative associations between testosterone and FSFI pain (β = -6.022, P = 0.044, Adj R2 = 0.050), between FAI and FSFI orgasm (β = -3.360, P = 0.023, Adj R2 = 0.049) and between androstenedione and clinical sexual distress (β = -7.293, P = 0.036, exp(β) = 0.001). LIMITATIONS, REASONS FOR CAUTION: The focus of the study on sexual functioning potentially creates selection bias. Possibly women with more severe sexual disturbances did or did not choose to participate. Differences between women with PCOS and controls in relationship duration and hormonal contraceptive use might have skewed the sexual function outcomes. WIDER IMPLICATIONS OF THE FINDINGS: Sexual function is impaired in women with PCOS. However, endocrine perturbations seem to have minimal direct impact on sexual function. Addressing sexuality and offering psychosexual counseling is important in the clinical care for women with PCOS. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by the departments of the participating centers: Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Erasmus University Medical Center, Rotterdam, the Netherlands; Department of Psychosomatic OBGYN and Sexology, Leiden University Medical Center, Leiden, the Netherlands; and Department of Sexology and Psychosomatic OBGYN, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands. J.S.E.L. received unrestricted research grants from the following companies (in alphabetical order): Ansh Labs, Ferring, Merck Serono and Roche Diagnostics. He also received consultancy fees from Ansh Labs, Ferring, Titus Healthcare and Roche Diagnostics. The other authors have no conflicts of interest. TRIAL REGISTRATION NUMBER: CCMO register, registration number: NL55484.078.16, 10 March 2016. https://www.toetsingonline.nl/to/ccmo_search.nsf/Searchform?OpenForm.
引用
- Pastoor H, Both S, Laan ETM, et al. Sexual dysfunction in women with PCOS: a case control study. Hum Reprod. 2023. PMID: 37776157. doi:10.1093/humrep/dead193
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。